Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.72), $0.01 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $15.29 million versus the consensus estimate of $15.19 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.